Exploiting Circulating Tumour Cells in the Battle Against Prostate Cancer

One of the greatest challenges in the treatment of prostate cancer comes when the cancer leaves the primary site of the prostate, moves through the bloodstream, to the site of a vital organ and forms a tumour. A process known as metastases.  In the London, Ontario lab of  Dr. Alison Allan and Tracey Sexton research is underway to measure circulating tumour cells (CTCs) as a means of predicting which patients are at the highest risk for recurrence of prostate cancer. Dr. Allan’s lab has 1 of 6 machines in Canada capable of detecting and accurately measuring CTCs. Read more in this week’s Londoner